glp 1 drugs and anxiety The Unexpected Mental Health Effect of GLP-1 Medications An analysis on the role

Lofton HF, Hold RP, Fielding G, Schwack B, Kaufman L, Oksman Z, et al

Integrated Single-Cell DNA and Mass Cytometry Analysis Reveals Treatment Induced Changes in Clonal Architecture and Immunophenotypes in TP53-mut AML

Targeting renal cell carcinoma with a HIF-2 antagonist

Bulking phase (muscle building): Lower doses (0.5 to 2 mg/week) for appetite control without excessive satiety

5.6 Personalized medicine and holistic approaches The increasing knowledge of the gut-brain-kidney axis offers the potential for personalized treatments, especially in CKD patients

Here we describe GLP-1 positive cells in the rat and human stomach and found these cells co-expressing ghrelin or somatostatin and able to secrete active GLP-1 in the rats